Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Current Investments: 2014-2025

Historic Cash & Current Investments for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to $257.8 million.

  • ImmunityBio's Cash & Current Investments rose 97.76% to $257.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $622.9 million, marking a year-over-year decrease of 20.68%. This contributed to the annual value of $149.8 million for FY2024, which is 43.78% down from last year.
  • Per ImmunityBio's latest filing, its Cash & Current Investments stood at $257.8 million for Q3 2025, which was up 67.78% from $153.7 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Cash & Current Investments registered a high of $317.1 million during Q4 2021, and its lowest value of $46.0 million during Q2 2023.
  • Its 3-year average for Cash & Current Investments is $157.7 million, with a median of $153.7 million in 2025.
  • As far as peak fluctuations go, ImmunityBio's Cash & Current Investments crashed by 66.20% in 2022, and later skyrocketed by 374.34% in 2024.
  • Over the past 5 years, ImmunityBio's Cash & Current Investments (Quarterly) stood at $317.1 million in 2021, then crashed by 66.20% to $107.2 million in 2022, then skyrocketed by 148.60% to $266.5 million in 2023, then tumbled by 43.78% to $149.8 million in 2024, then skyrocketed by 97.76% to $257.8 million in 2025.
  • Its Cash & Current Investments was $257.8 million in Q3 2025, compared to $153.7 million in Q2 2025 and $61.6 million in Q1 2025.